Stock BIOBLAST PHARMA LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Bioblast Pharma Ltd Nasdaq

Equities

IL0011319527

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enlivex Therapeutics : Report of Periodic or Interim Report
PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
GL
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial
MT
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
AQ
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis
CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark
MT
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
GL
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care
MT
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
GL
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study
MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis
CI
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K
PU
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.
CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENLV Stock
  4. Stock
  5. News Bioblast Pharma Ltd